Clinical Trial Update: AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating batiraxcept (AVB-500) in combination with paclitaxel for recurrent high-grade endometrial cancer has been withdrawn from ClinicalTria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Batiraxcept (AVB-500) (batiraxcept)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Recurrent High Grade Uterine Cancer | Phase 1 | Status: WITHDRAWN